Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Depreciation & Amortization (CF) (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $5600.0 as the latest value for Q3 2025.

  • Quarterly Depreciation & Amortization (CF) fell 88.01% to $5600.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $77900.0 through Dec 2025, down 61.11% year-over-year, with the annual reading at $79000.0 for FY2025, 59.07% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $5600.0 at Whitehawk Therapeutics, down from $15300.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $74000.0 in Q1 2022, with the low at $2000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $37431.6, with a median of $44000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) soared 3600.0% in 2022, then plummeted 88.01% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $72000.0 in 2021, then plummeted by 36.11% to $46000.0 in 2022, then dropped by 4.35% to $44000.0 in 2023, then grew by 22.73% to $54000.0 in 2024, then crashed by 89.63% to $5600.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $5600.0, $15300.0, and $57000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.